Biogen BIIB RITUXAN — After Second GAZYVA Threshold Date

Similar metrics at other companies

LGNDRylaze — Total revenue and income

$3.22M+3.3%

ALKSRISPERDALCONSTA — Collaborative Arrangement Royalty Rate Upon Termination Of Related Agreement

1.3%0.0pp

LGNDRylaze — Total revenues and income

$3.22M+3.3%

JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax

$103.7M+10.1%

ZYMERoyalties — Research and development collaborations

$1.33M+558%

INCYTABRECTA Royalty Revenues — Total revenues

$5.98M-6.7%

Questions, answered.

What is Biogen's RITUXAN — after second GAZYVA threshold date?

Biogen (BIIB) reported RITUXAN — after second GAZYVA threshold date of 35% in Q1 2026.

How has Biogen's RITUXAN — after second GAZYVA threshold date changed year-over-year?

Biogen's RITUXAN — after second GAZYVA threshold date decreased by 0.0% year-over-year, from 35% to 35%.

What is the long-term trend for Biogen's RITUXAN — after second GAZYVA threshold date?

Over 2 years (2023 to 2025), Biogen's RITUXAN — after second GAZYVA threshold date has grown at a 0.0% compound annual growth rate (CAGR), from 140% to 140%.

What does RITUXAN — after second GAZYVA threshold date mean?

This metric defines the profit-sharing or royalty structure applicable to a product collaboration following the achievement of a secondary milestone by a related drug. It represents the post-milestone economic phase where the partnership terms are adjusted based on the success of the secondary product. This is essential for modeling long-term revenue expectations from the collaboration.